FDA approves Genentech’s Lucentis PFS

Genentech's 0.5 mg prefilled syringe (PFS) Lucentis has been approved by the U.S. Food and Drug Administration as a new means to administer the medication.
The new PFS is designed for the treatment of patients who have wet age-related macular degeneration (AMD) as well as macular edema after retinal vein occlusion (RVO) just like the Lucentis 0.5 mg vial. With the approval by the FDA, the Lucentius PFS has become the first approved PFS containing an anti-VEGF medication designed to treat two eye conditions.
“The FDA approval of the Lucentis prefilled syringe marks a new milestone in our ongoing commitment to people affected by vision-threatening eye diseases,” Genentech CMO and Head of Global Product Development Dr. Sandra Horning said. “With the PFS, physicians will have a new option for administering Lucentis to the hundreds of thousands of people in the U.S. diagnosed with either wet AMD or macular edema after RVO.”
With the new Lucentis PFS, physicians will now be allowed to do away with a number of steps in the processes of perpetration and administration. This includes vial disinfecting, filter needle attachment and drawing the medication from the vial using the needle.